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The current deceased-donor kidney allocation system in the U.S. has been in existence for more than 20 years. Over the last 4 years 
there has been a dedicated effort toward the 
development of a new system of transplant 
allocation. The development of a new kid-
ney allocation system has been driven by 
the competing goals of improving the util-
ity of kidney transplantation and enhanc-
ing the equity of the system. A number of 
trends in kidney transplantation informed 
the framers of the new allocation system 
proposal. The average age of waitlisted can-
didates has increased (Figure 1), resulting 
in the transplantation of older candidates 
with multiple cardiovascular comorbidities. 
Consequently, there has been a marked 
increase in recipients dying with otherwise 
functional allografts1 and a simultaneous 
decline in estimated post-transplant survival 
(Figure 2). In addition, much of the work on 
the system revision has been driven by an 
interest in eliminating extreme mismatches 
between donor kidney and recipient surviv-
als. This article reviews the history of the 
development of the new allocation system 
proposal, discusses the expected outcomes 
if such a proposal is adopted, and discusses 
the progress to date toward implementation 
of a new kidney allocation system.
Revision of the Allocation 
System
The fi rst steps toward revision of the alloca-
tion system began in 2004 when the Organ 
Procurement Transplant Network (OPTN) 
Board of Directors charged the Kidney 
Transplantation Committee (KTC) with 
performing a comprehensive review of the 
current allocation algorithm. The subse-
quent kidney allocation review subcom-
mittee (KARS) report concluded that the 
allocation system was inequitable, lacked 
predictability, and did not effectively uti-
lize the potential life years available from 
donor kidneys.2 The current system was 
also shown to be no longer consistent with 
sections of the National Organ Transplant 
Act (NOTA) of 19843 or the OPTN Final 
Rule,4 the 2 directives that guide organ 
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allocation in the U.S. Specifi cally, NOTA 
directs that the allocation system be based 
on established medical criteria and function 
to increase transplantation among popula-
tions with special needs, including ethnic 
minority groups and sensitized candidates; 
the OPTN Final Rule instructs that alloca-
tion policy be based on sound medical 
judgment; seek to achieve the best use of 
donated organs; be designed to avoid wast-
ing organs; and to promote the effi cient 
management of organ placement. 
The KTC recognized that the current 
system, with its emphasis on waiting time, 
non-biologic point scores for matching and 
sensitization, and a limited defi nition of 
donor quality did not adequately achieve 
the allocation directives. The KTC was 
instructed to address the limitations identi-
fi ed by their review through revision of the 
adult kidney transplant allocation system. 
The KTC began to explore integrating 
a measure of medical benefi t into a new 
allocation system. The result has been the 
development of a new national allocation 
system proposal that would transplant wait-
listed candidates on the basis of a kidney 
allocation score (KAS).
Components of the Kidney 
Allocation Score
Life Years from Transplant
The underlying considerations in the KAS 
are very similar to those of the current allo-
cation system (Table I). Both systems con-
tain medical criteria, recognition of waiting 
time and sensitization, along with measures 
of donor quality. In the current allocation 
system, the major medical criterion for 
allocation is human leukocyte antigen 
(HLA) matching. The use of HLA func-
tions to maximize allograft survival and 
currently priority is based on the number of 
HLA-DR matches between donor and 
recipient. In the KAS-based system, the 
major medical consideration becomes life 
years from transplant (LYFT). The LYFT 
calculation describes the difference between 
the life expectancy of a candidate with a 
deceased-donor transplant from a specifi c 
donor compared to the candidates expected 
survival if they were not transplanted.5 In 
contrast to HLA matching, LYFT seeks to 
optimize recipient survival and introduces 
for the fi rst time a patient-centered utility 
measure into kidney allocation. The LYFT 
calculation takes into account a number of 
measurable factors that are known to affect 
long-term recipient survival including HLA 
matching, where HLA is assigned a weight 
based on its biologic effect on post-trans-
plant survival (Table II). In addition, there 
is a quality of life (QoL) adjustment to the 
LYFT calculation, with the recognition that 
life with a functioning transplant is superior 
to that experienced on the waitlist or after 
graft failure. All candidate and recipient 
life years without a functioning transplant 
are discounted to 80% of the value of a
œ
 
TABLE I. Comparison of the current allocation system and the KAS 
system.
Current KAS
Medical Criteria HLA LYFT
Waiting Time Active waitlist DT
Sensitization 4 points for % PRA  or  80% 4 x % PRA/100 
Donor SCD/EC Donor profi le
Abbreviations: KAS, kidney allocation score; HLA, human leukocyte antigen; LYFT, life years from transplant; 
DT, dialysis time; PRA, panel reactive antibody; SCD, standard criteria donor; ECD, extended criteria donor; 
DPI, donor profi le index.
TABLE II. Covariates in the life years from transplant calculation.
Recipient Factors Donor Factors
Age Age
Transplant type (K or SPK) DSA relation to recipient
Recipient diagnosis Cause of death
Previous transplant Deceased after cardiac death
Peak panel reactive antibodies Human leukocyte antigens (A, B, DR)
Albumin Cytomegalovirus status
Years on dialysis Hypertension
Body mass index Weight
Abbreviations: K or SPK, kidney or simultaneous kidney-pancreas; DSA, donor service area 
FIGURE 2. Average of estimated median post-transplant survival by year of transplant. An estimat-
ed survival curve was generated for each recipient and the median survival in years was determined. 
The average was taken of the median survival for all recipients in each given year of transplant. 
Source: Mccullough Kp, Leichtman Ab, Port Fk, Wolfe Ra. Trends In Kidney Recipient Age And 
Survival Benefi t Due To Transplant By Year. Am J Transplant. 2007;7(suppl 2):231.
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transplanted year of life, resulting in QoL 
adjusted LYFT which is used in the KAS.
Dialysis Time
In a KAS-based system, waiting time is 
calculated from the date of fi rst mainte-
nance dialysis (expressed as dialysis time 
[DT]) in contrast to the current practice 
of using the date of fi rst active waitlisting. 
Because the majority of candidates have 
initiated maintenance dialysis before the 
date of transplant evaluation, the waiting 
time often has little relation to the onset of 
end-stage kidney disease (ESRD). Minority 
candidates in particular tend to be listed 
after longer periods of time on dialysis 
than their majority counterparts and are 
disadvantaged by current waitlisting prac-
tice. Use of DT instead of waitlist time 
helps equalize access to transplant oppor-
tunities among candidates and has been in 
use in the states of Michigan, California, 
and Iowa as part of the Kidney Dialysis 
Wait Time Study.6 In addition to DT, there 
has been broad support for preserving the 
opportunity for waitlisting prior to dialy-
sis in order to maintain the possibility of 
pre-emptive transplantation.
Donor Profi le Index
Deceased-donor kidneys are currently char-
acterized as either standard criteria (SCD) 
or extended criteria donor (ECD) organs. 
The ECD defi nition identifi es a group of 
kidneys with a higher risk for allograft 
failure than that of SCD organs.7 Extended 
criteria donor organs are recognized to have 
a higher discard rate than SCD organs, 
presumably on the basis of physician con-
cerns for organ quality.8 As it happens, 
however, there is substantial overlap in 
the distribution of allograft survivals seen 
among SCD and ECD organs (Figure 3). In 
the KAS proposal, the Donor Profi le Index 
(DPI) replaces the current SCD/ECD dif-
ferentiation.9 In contrast to the SCD/ECD 
dichotomy, the DPI provides a continuous 
measure of donor quality. Donor quality 
is evaluated as the expected risk of long-
term allograft failure. The DPI is expressed 
numerically as a value ranging from 0 (the 
longest-lived kidneys) to 1 (the shortest 
expected graft survivals). The DPI provides 
transplant professionals with very specifi c 
information that can be used to consider 
each offer relative to the intended recipient. 
The DPI holds the promise of improved 
effi ciency in the utilization of marginal 
kidneys by allowing physicians to more 
confi dently match different quality donor 
kidneys to the appropriate candidates who 
could benefi t from them.
Sensitization
One more consideration that has been inte-
grated into the KAS proposal has been to 
redefi ne how candidate sensitization is pri-
oritized. In the current allocation system, 
candidates with panel reactive antibodies 
(PRA) 80% are given the equivalent of 
4 years of waiting time to prioritize them 
on the waiting list if a crossmatch nega-
tive organ becomes available. Candidates 
with PRA <80% receive no priority and 
are relatively disadvantaged. In addition, 
there is an incentive for transplant centers 
to report the highest PRA obtained from a 
candidate in order to gain priority points, 
even if the antigens identifi ed would not 
preclude transplantation at that center. 
More consistent with the disadvantage of 
increasing PRA is to introduce a sliding 
scale of allocation consideration such that 
candidates receive priority points on a 
4 times PRA divided by 100 (PRA  
4/100) scale for continuous accounting 
of sensitization. As the histocompatibil-
ity community has moved increasingly 
toward using calculated PRA (CPRA),10,11 
that is, the likelihood of a positive cross-
match given a candidate’s antigens and 
his local donor pool, CPRA is used in the 
KAS proposal.
The concepts of LYFT, DT, DPI, and 
CPRA have been integrated into a kid-
ney allocation score (Figure 4). The KAS 
is calculated for each candidate when a 
particular donor kidney (with its specifi c 
DPI) becomes available. The mathemati-
cal expression of the KAS shows that for 
a given candidate, as the expected survival 
of the donor organ decreases, the fraction 
FIGURE 3. Distribution of relative risk for graft failure among standard criteria (SCD) and extended 
criteria donor (ECD) organs. 
Source: Modifi ed From Data Contained in Rao PS, et al. Comprehensive Risk Quantifi cation Score 
For Deceased-Donor Kidneys: The Kidney Donor Risk Index. Transplantation. 2009;88(2):231-236 
And Presentations To The KTC in 2009.
FIGURE 4. Kidney Allocation Score Calculation. Source: Kidney Allocation Concepts, Request 
for Information. Issued by: The OPTN/UNOS Kidney Transplantation Committee. Circulated for 
Consideration September 24, 2008 through December 18, 2008. http://www.optn.transplant.
hrsa.gov/SharedContentDocuments/KidneyAllocationSystem-RequestForInormation.pdf. Accessed 
July 26, 2009.
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of the LYFT score considered in the KAS 
decreases and the fraction of DT considered 
in the score increases. For candidates com-
peting for very long-lived organs, consider-
ation of the projected survival of the candi-
date (LYFT) is very important to maximize 
potential allograft years. For kidneys with 
shorter projected survival, DT becomes 
more important such that sicker candidates 
with lower LYFT scores and long dialysis 
histories can still be competitive for kidneys 
that may improve their lives. Similar to 
candidates in the current system with little 
waitlist time, candidates in the KAS system 
with both poor LYFT scores and little DT 
will not be competitive for organs.
Expected Outcomes From 
KAS-Based Allocation
Compared to the current system, an alloca-
tion system utilizing the KAS as proposed 
is projected to achieve an additional 3,400 
years of life for patients for each year of 
deceased-donor allocation.12 The additional 
life years are largely achieved by shifting long 
and moderately lived kidneys into younger 
candidates. Because younger candidates 
transplanted with better kidneys are likely to 
realize the full allograft survival, substantial 
life years are gained over the current system 
by KAS-based allocation. In addition, using 
the KAS, the number of transplants is expect-
ed to improve for African Americans, candi-
dates with ESRD from glomerulonephritis 
and hypertension (Figure 5), and moderately 
sensitized individuals (not shown). The main 
patient groups with lower transplantation 
rates under the KAS compared to the current 
system are expected to be candidates over 
the age of 50 years, particularly those with 
diabetes mellitus (DM).
Progress to Date
In the last 4 years there has been signifi cant 
effort to develop a new allocation system 
based on the KAS. More than 28 sets of 
allocation algorithms were considered prior 
to arriving at the current proposal.2 A num-
ber of them, particularly the pure LYFT-
based systems achieved substantially more 
life-years from transplant, but at a cost of 
decreased equity in the system. Currently, 
the use of DPI, DT, and PRA in alloca-
tion has been widely embraced by the 
FIGURE 5. Model of outcomes in the current system and KAS: A. By recipient age category; 
B. By recipient race; C. By recipient ESRD diagnosis. For each fi gure, the header represents 
the percent of active waitlist candidates that have each characteristic considered for outcome. 
Source: Kidney Allocation Concepts, Request for Information. Issued by: The OPTN/UNOS Kidney 
Transplantation Committee. Circulated 9-24-2008 through 12-18-2008. Available at: optn.trans-
plant.hrsa.gov/SharedContentDocuments/KidneyAllocationSystem—RequestForInformation.pdf. 
Accessed August 13, 2009.
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transplant community. In addition, most 
stakeholders support the concept of better 
matching of recipient and allograft surviv-
als even when LYFT itself has not been 
specifi cally supported. Although the KAS 
proposal improves on the current allocation 
system substantially, there are a number of 
issues to be considered by the transplant 
community prior to implementation. These 
include discussion of patient groups likely 
to have decreased access to transplants, 
questions about the accuracy of the survival 
estimates used in the LYFT calculation, and 
the complexity and predictability of the 
KAS-based system.
Unlike the current system where wait-
list mortality is shared across all patient 
groups, it is clear that under the KAS sys-
tem, older candidates and diabetics above 
age 50 will have less access to trans-
plantation. Clearly, increasing age and the 
presence of diabetes decrease expectations 
for long-term survival. Also clear is that 
the shift of organs to younger candidates 
results in a net gain in total recipient life 
years. However, the fairness to decreasing 
access to a transplant on the basis of the 
biologic effects of age and DM and wheth-
er all DM should be considered equally 
(type 1, type 2, ESRD from DM, ESRD 
with DM) are issues still to be resolved. 
The use of age in the allocation system 
has been examined by the Department of 
Health and Human Services Offi ce of Civil 
Rights (OCR) to determine if there was any 
issue of age discrimination. The OCR has 
decided to reserve judgment until a revised 
system is approved.
There are 2 categories of questions 
about the LYFT calculation. The fi rst has 
to do with the relatively limited data from 
which the Scientifi c Registry of Transplant 
Recipients (SRTR) had available to make 
estimates of long-term recipient survival. 
Most prominently discussed is the absence 
of a specifi c measure of cardiovascular 
disease burden and how that might affect 
the accuracy of survival estimates. A sub-
committee of the KTC is being formed to 
examine this issue. The second surrounds 
the accuracy with which LYFT can differ-
entiate the survival of pairs of candidates on 
the waiting list. The accuracy with which 
LYFT can correctly order the survival of 
candidate pairs has been assessed by look-
ing at the index of covariance or C-statistic 
of the model. A model with a C-statistic of 
0.5 has a 50-50 chance of correctly rank-
ing the survival of 2 candidates. The 
overall C-statistics for the components of 
LYFT range from 0.61 to 0.68.13 However, 
this underestimates the value of the LYFT 
calculation. For candidates who are medi-
cally similar, LYFT provides estimates 
of survival that are very similar, but for 
candidate pairs who are medically dis-
similar, the accuracy of LYFT for ordering 
survival increases substantially (C-statistic 
0.9). Comparison with other models 
used for allocation show LYFT is com-
parable or better than the C-statistics for 
waitlist survival in the liver allocation 
model for end-stage liver disease (MELD; 
0.64) and post-transplant survival in the 
lung allocation score (LAS; 0.59). In the 
case of both MELD and the LAS there is 
agreement that these systems work well, 
serve the patient interests, and are signifi -
cant improvements from their respective 
previous allocation systems.
Building community consensus has 
been as much a part of the KAS proposal 
as development of the score itself. There 
is always inertia to remain with the status 
quo in the face of such a large change, 
even if the current system is inferior to 
the proposed revision. The KAS proposal 
describes a system that is clearly more 
predictable than the current system but at 
the same time, somewhat more complex. 
Truthfully, the complexity is in the calcu-
lations themselves, not the concepts, but 
concern over patient perception has been 
a prominent part of system development 
discussion. All parties agree on the impor-
tance that patients perceive the allocation 
system to be fair. As such, the level of 
complexity that can be introduced in the 
name of system improvement versus the 
transparency necessary for patient trust will 
be a critical issue.14
There have been two public forums, a 
formal request for information (RFI) from 
the KTC along with deliberate engage-
ment of more than 20 transplant and non-
transplant organizations with a stake in 
the outcome of a revised kidney allo-
cation system.12 Based on feedback to 
the RFI and comments from the forums, 
the next steps in proposal development 
will likely involve modeling of alterna-
tives to LYFT. Most alternatives to date 
have involved systems that were less equi-
table (direct age matching), imposed arbi-
trary cutoffs for candidate priority (donors 
<35 years old being offered to candidates 
<35 years old),15 or have suggested alloca-
tion of only some candidates by LYFT and 
the remainder by waiting time.16 Many 
additional alternatives will likely follow in 
the near future.
In the OPTN Board of Directors meet-
ing, June 23, 2009 and a recent article, the 
outgoing Chairman of the KTC presented 
the progress to date on allocation system 
revision and outlined a suggested path 
forward for a system emphasizing dialysis 
time, estimated post-transplant recipient 
survival, and a suggestion to limit the 
best quality kidneys to the candidates 
with the highest estimated survivals.17,18 
The system would likely involve the phas-
ing in of DT and DPI in the near future 
and integration of the utility measure at 
a later date once it was refi ned. Integral 
to the Chairman’s suggestions were the 
preservation of patient choice in accepting 
kidneys and fl exibility for transplant cen-
ters to focus on individual patient needs 
by specifying acceptable HLA matches. 
Each of the recent suggestions still needs 
to be modeled and compared with the 
current and KAS systems before any 
new allocation system proposal can be 
fi nalized.
Conclusions
The most substantial revision of the adult 
kidney transplant allocation system since 
its inception is underway. More than 
4 years of effort have gone into the devel-
opment of the current KAS proposal. The 
KAS incorporates, for the fi rst time, a mea-
sure of medical benefi t into an allocation 
algorithm. As simulated, the KAS holds the 
promise of better resource utilization, 
improved predictability, and signifi cant 
improvement in the life years available to 
recipients following transplantation. The 
proposal still faces several challenges to 
approval and implementation, not the least 
of which is patient and provider readiness 
to move to a new system. At the end of the 
process, however, there is hope for a new 
deceased-donor allocation system that 
functions to transplant candidates effi cient-
ly and equitably, using medically-based 
criteria. D&T
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